Co-Diagnostics

Co-Diagnostics Receivables

The Accounts Receivable of Co-Diagnostics (CODX) as of Oct 30, 2026 is 132,600.00 USD. In the previous year, Accounts Receivable was 303,900.00 USD — a change of -56.37% (lower).

Receivables

132,600.00USD

YoY

-56.37%

Last updated:

Accounts Receivable of Co-Diagnostics is 2024 132,600.00 USD. Accounts Receivable of Co-Diagnostics was 2023 303,900.00 USD. It decreases by -56.37% lower compared to the previous year.

The Co-Diagnostics Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
0.00 USD
Jan 1, 2019
100,000.00 USD
Jan 1, 2020
12.10 M USD
Jan 1, 2021
20.80 M USD
Jan 1, 2022
3.50 M USD
Jan 1, 2023
303,900.00 USD
Jan 1, 2024
132,600.00 USD
The Co-Diagnostics Receivables history
YEARReceivablesYoY
132,600.00USD-56.37%
303,900.00USD-91.32%
3.50 MUSD-83.17%
20.80 MUSD+71.90%
12.10 MUSD+12,000.00%
100,000.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Accounts Receivable of Co-Diagnostics is 132,600.00 USD in 2024.

Accounts Receivable of Co-Diagnostics changed from 303,900.00 USD to 132,600.00 USD, representing a -56.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Co-Diagnostics

All Key Metrics — Co-Diagnostics